S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Crinetics Pharmaceuticals Stock Forecast, Price & News

-1.31 (-5.04%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
210,999 shs
Average Volume
264,275 shs
Market Capitalization
$1.17 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Crinetics Pharmaceuticals logo

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.


Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 9%
December 2, 2021 |  americanbankingnews.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $24.40
November 30, 2021 |  americanbankingnews.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading Down 12.7%
November 26, 2021 |  americanbankingnews.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $25.53
November 24, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$70 thousand
Price / Sales
Book Value
$4.08 per share


Net Income
$-73.81 million
Pretax Margin




Free Float
Market Cap
$1.17 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.34 out of 5 stars

Medical Sector

249th out of 1,390 stocks

Pharmaceutical Preparations Industry

104th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

Is Crinetics Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals
or view top-rated stocks.

How has Crinetics Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRNX stock has increased by 59.1% and is now trading at $24.66.
View which stocks have been most impacted by COVID-19

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a drop in short interest in October. As of October 29th, there was short interest totaling 1,170,000 shares, a drop of 17.0% from the October 14th total of 1,410,000 shares. Based on an average trading volume of 265,800 shares, the days-to-cover ratio is presently 4.4 days. Currently, 3.4% of the company's shares are sold short.
View Crinetics Pharmaceuticals' Short Interest

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Crinetics Pharmaceuticals

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings data on Friday, November, 5th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.01.
View Crinetics Pharmaceuticals' earnings history

What price target have analysts set for CRNX?

6 analysts have issued 12-month price objectives for Crinetics Pharmaceuticals' shares. Their forecasts range from $28.00 to $45.00. On average, they anticipate Crinetics Pharmaceuticals' share price to reach $36.80 in the next twelve months. This suggests a possible upside of 49.2% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:
  • Scott R. Struthers, President, Chief Executive Officer & Director
  • Jeff E Knight, Chief Operating Officer
  • Marc J. S. Wilson, Chief Financial Officer
  • Robert Flath, Finance Director
  • Alan Seth Krasner, Chief Medical Officer

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.79%), BVF Inc. IL (2.01%), Wellington Management Group LLP (1.92%), Sphera Funds Management LTD. (1.16%), Geode Capital Management LLC (1.09%) and Point72 Asset Management L.P. (0.95%). Company insiders that own Crinetics Pharmaceuticals stock include Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephen F Betz and Vivo Capital Viii, Llc.
View institutional ownership trends for Crinetics Pharmaceuticals

Which major investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including Altium Capital Management LP, Point72 Asset Management L.P., Morgan Stanley, Sphera Funds Management LTD., Citadel Advisors LLC, California State Teachers Retirement System, Goldman Sachs Group Inc., and New York State Common Retirement Fund. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, Richard Scott Struthers, and Stephen F Betz.
View insider buying and selling activity for Crinetics Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, BioImpact Capital LLC, Opaleye Management Inc., Wellington Management Group LLP, Dimensional Fund Advisors LP, Victory Capital Management Inc., Russell Investments Group Ltd., and Two Sigma Advisers LP. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Perceptive Advisors Llc, and Richard Scott Struthers.
View insider buying and selling activity for Crinetics Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $24.66.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals has a market capitalization of $1.17 billion and generates $70 thousand in revenue each year. The company earns $-73.81 million in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals employs 93 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Where are Crinetics Pharmaceuticals' headquarters?

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at (858) 450-6464 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.